Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
24 05 2022
Historique:
received: 19 08 2021
accepted: 16 01 2022
pubmed: 28 1 2022
medline: 25 5 2022
entrez: 27 1 2022
Statut: ppublish

Résumé

Factor XII (FXII) is the zymogen of a plasma protease (FXIIa) that contributes to bradykinin generation by converting prekallikrein to the protease plasma kallikrein (PKa). FXII conversion to FXIIa by autocatalysis or PKa-mediated cleavage is enhanced when the protein binds to negatively charged surfaces such as polymeric orthophosphate. FXII is composed of noncatalytic (heavy chain) and catalytic (light chain) regions. The heavy chain promotes FXII surface-binding and surface-dependent activation but restricts activation when FXII is not surface bound. From the N terminus, the heavy chain contains fibronectin type 2 (FN2), epidermal growth factor-1 (EGF1), fibronectin type 1 (FN1), EGF2, and kringle (KNG) domains and a proline-rich region. It shares this organization with its homolog, pro-hepatocyte growth factor activator (Pro-HGFA). To study the importance of heavy chain domains in FXII function, we prepared FXII with replacements of each domain with corresponding Pro-HGFA domains and tested them in activation and activity assays. EGF1 is required for surface-dependent FXII autoactivation and surface-dependent prekallikrein activation by FXIIa. KNG and FN2 are important for limiting FXII activation in the absence of a surface by a process that may require interactions between a lysine/arginine binding site on KNG and basic residues elsewhere on FXII. This interaction is disrupted by the lysine analog ε-aminocaproic acid. A model is proposed in which an ε-aminocaproic acid-sensitive interaction between the KNG and FN2 domains maintains FXII in a conformation that restricts activation. Upon binding to a surface through EGF1, the KNG/FN2-dependent mechanism is inactivated, exposing the FXII activation cleavage site.

Identifiants

pubmed: 35086137
pii: 483732
doi: 10.1182/bloodadvances.2021005976
pmc: PMC9131904
doi:

Substances chimiques

Fibronectins 0
Factor XII 9001-30-3
Prekallikrein 9055-02-1
Lysine K3Z4F929H6
Aminocaproic Acid U6F3787206

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3142-3154

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL130018
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144113
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Proc Natl Acad Sci U S A. 1981 Feb;78(2):829-33
pubmed: 6940150
J Biol Chem. 1989 Jul 5;264(19):11497-502
pubmed: 2472397
J Biol Chem. 1989 Aug 5;264(22):12941-9
pubmed: 2473984
J Biol Chem. 1993 Oct 25;268(30):22927-32
pubmed: 8226803
J Biol Chem. 1992 Jun 25;267(18):12528-38
pubmed: 1618758
J Clin Invest. 1955 Apr;34(4):602-13
pubmed: 14367514
J Thromb Haemost. 2012 Jul;10(7):1385-96
pubmed: 22540246
Amyloid. 2008 Sep;15(3):166-80
pubmed: 18925455
Thromb Haemost. 2020 Mar;120(3):400-411
pubmed: 31940673
J Biol Chem. 2020 Jan 10;295(2):363-374
pubmed: 31771982
J Thromb Haemost. 2016 Mar;14(3):427-37
pubmed: 26707513
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2229-2234
pubmed: 33746090
J Biol Chem. 1985 Nov 5;260(25):13666-76
pubmed: 3877053
Blood. 2017 Mar 16;129(11):1527-1537
pubmed: 28069606
Blood. 2014 Mar 13;123(11):1739-46
pubmed: 24408325
Adv Exp Med Biol. 1986;198 Pt B:27-34
pubmed: 3492870
J Biol Chem. 1993 May 15;268(14):10024-8
pubmed: 7683665
Eur J Biochem. 1996 May 15;238(1):240-9
pubmed: 8665943
Blood Adv. 2020 Dec 22;4(24):6135-6147
pubmed: 33351111
J Thromb Haemost. 2016 Jan;14(1):28-39
pubmed: 26565070
Adv Exp Med Biol. 1989;247A:473-6
pubmed: 2481390
Blood. 2019 Mar 7;133(10):1152-1163
pubmed: 30591525
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Feb 1;69(Pt 2):94-102
pubmed: 23385745
J Allergy Clin Immunol. 2016 Nov;138(5):1414-1423.e9
pubmed: 27130860
Blood. 1995 Dec 1;86(11):4134-43
pubmed: 7492770
Blood Rev. 2015 Jan;29(1):17-24
pubmed: 25294122
Trends Cardiovasc Med. 2003 Jan;13(1):21-30
pubmed: 12554097
Biochem Biophys Res Commun. 1993 Feb 26;191(1):110-7
pubmed: 8447816
Nat Commun. 2020 Jan 10;11(1):179
pubmed: 31924766
Thromb Res. 1988 Jan 15;49(2):253-63
pubmed: 3129817
Semin Thromb Hemost. 1978 Summer;5(1):27-40
pubmed: 568312
Biochem Biophys Res Commun. 2006 May 19;343(4):1286-9
pubmed: 16638441
Thromb Haemost. 2000 Dec;84(6):1057-65
pubmed: 11154114
J Thromb Haemost. 2008 Nov;6(11):1876-83
pubmed: 18761718
J Thromb Haemost. 2018 May 20;:
pubmed: 29779246
J Thromb Haemost. 2016 Aug;14(8):1498-506
pubmed: 27282310
Eur J Biochem. 1985 Sep 16;151(3):531-8
pubmed: 3875484
Curr Opin Struct Biol. 2013 Dec;23(6):836-41
pubmed: 24252474
Cell Mol Bioeng. 2020 Oct 13;14(2):161-175
pubmed: 33868498
Curr Opin Hematol. 2017 Sep;24(5):411-418
pubmed: 28604413
J Thromb Haemost. 2019 Dec;17(12):2131-2140
pubmed: 31420909
Nat Commun. 2021 Sep 22;12(1):5596
pubmed: 34552086
Blood. 2018 Apr 26;131(17):1903-1909
pubmed: 29483100
Cell Rep. 2012 Mar 29;1(3):185-90
pubmed: 22832192
J Thromb Haemost. 2019 Jan;17(1):183-194
pubmed: 30394658

Auteurs

Aleksandr Shamanaev (A)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Ivan Ivanov (I)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Mao-Fu Sun (MF)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Maxim Litvak (M)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Priyanka Srivastava (P)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Bassem M Mohammed (BM)

Edward A. Doisy Research Center, Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, St. Louis, MO.

Rabia Shaban (R)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Ashoka Maddur (A)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Ingrid M Verhamme (IM)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Owen J T McCarty (OJT)

Department of Biomedical Engineering, and.
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR; and.

Ruby H P Law (RHP)

Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.

David Gailani (D)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Articles similaires

Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
1.00
Saccharomyces cerevisiae Lysine Cell Nucleolus RNA, Ribosomal Saccharomyces cerevisiae Proteins

Amyloid accelerator polyphosphate fits as the mystery density in α-synuclein fibrils.

Philipp Huettemann, Pavithra Mahadevan, Justine Lempart et al.
1.00
Polyphosphates alpha-Synuclein Humans Amyloid Molecular Dynamics Simulation
Protein Processing, Post-Translational Humans Blood Coagulation Fibrin Fibrinogen

Classifications MeSH